{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Open+Label&page=19",
    "query": {
      "condition": "Open Label",
      "page": 19
    },
    "page_size": 10
  },
  "pagination": {
    "page": 19,
    "page_size": 10,
    "total_count": 17645,
    "total_pages": 1765,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Open+Label&page=20&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Open+Label&page=18&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T14:55:15.618Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05565378",
      "title": "A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer, Non-Small Cell"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Dostarlimab",
          "type": "DRUG"
        },
        {
          "name": "Belrestotug",
          "type": "DRUG"
        },
        {
          "name": "Nelistotug",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 351,
      "start_date": "2022-10-14",
      "completion_date": "2027-12-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-10-26T14:55:15.618Z",
      "location_count": 4,
      "location_summary": "Plantation, Florida • Albuquerque, New Mexico • Chattanooga, Tennessee + 1 more",
      "locations": [
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        },
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05565378"
    },
    {
      "nct_id": "NCT00122304",
      "title": "Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemoglobinuria, Paroxysmal"
      ],
      "interventions": [
        {
          "name": "eculizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2004-12",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2007-02-21",
      "last_synced_at": "2026-10-26T14:55:15.618Z",
      "location_count": 19,
      "location_summary": "Los Angeles, California • Stanford, California • Hartford, Connecticut + 15 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Weston",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00122304"
    },
    {
      "nct_id": "NCT07284433",
      "title": "Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma Diffuse Large B-cell",
        "Leukemia and Lymphoma",
        "Leukemia Relapse",
        "Lymphoma Receiving CAR-T Therapy"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide (Non-IMP, Lymphodepletion)",
          "type": "OTHER"
        },
        {
          "name": "Fludarabine (Non-IMP, Lymphodepletion)",
          "type": "OTHER"
        },
        {
          "name": "Allo-QuadCAR01-T",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "AvenCell Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 178,
      "start_date": "2026-01-06",
      "completion_date": "2029-11-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-10-26T14:55:15.618Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • Evanston, Illinois • Providence, Rhode Island + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07284433"
    },
    {
      "nct_id": "NCT01526785",
      "title": "A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pompe Disease"
      ],
      "interventions": [
        {
          "name": "Alglucosidase alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 113,
      "start_date": "2012-03",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2015-12-08",
      "last_synced_at": "2026-10-26T14:55:15.618Z",
      "location_count": 51,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 48 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01526785"
    },
    {
      "nct_id": "NCT02980068",
      "title": "A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pulmonary; Hypertension",
        "Heart Failure",
        "Preserved Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "15N Nitrate",
          "type": "DRUG"
        },
        {
          "name": "14N Nitrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gladwin, Mark, MD",
      "sponsor_class": "INDIV",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2017-08-28",
      "completion_date": "2022-02-25",
      "has_results": false,
      "last_update_posted_date": "2022-03-22",
      "last_synced_at": "2026-10-26T14:55:15.618Z",
      "location_count": 2,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02980068"
    },
    {
      "nct_id": "NCT03563391",
      "title": "A Study to Evaluate the Effects of a New Formula on the Growth, Safety and Tolerance of Infants With Growth Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Growth Failure",
        "Congenital Heart Disease"
      ],
      "interventions": [
        {
          "name": "New Infant Formula",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Nutricia North America",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "8 Months",
        "sex": "ALL",
        "summary": "1 Month to 8 Months"
      },
      "enrollment_count": 30,
      "start_date": "2018-01-30",
      "completion_date": "2020-05-30",
      "has_results": false,
      "last_update_posted_date": "2020-12-08",
      "last_synced_at": "2026-10-26T14:55:15.618Z",
      "location_count": 5,
      "location_summary": "Jacksonville, Florida • Atlanta, Georgia • Greenville, North Carolina + 2 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03563391"
    },
    {
      "nct_id": "NCT07781891",
      "title": "RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ewing Sarcoma"
      ],
      "interventions": [
        {
          "name": "LX-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2027-02-01",
      "completion_date": "2033-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-10-26T14:55:15.618Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07781891"
    },
    {
      "nct_id": "NCT03148418",
      "title": "A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 382,
      "start_date": "2017-09-20",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-26T14:55:15.618Z",
      "location_count": 44,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • San Marcos, California + 36 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Marcos",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03148418"
    },
    {
      "nct_id": "NCT06094790",
      "title": "A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "CORT125134 150 mg",
          "type": "DRUG"
        },
        {
          "name": "CORT125134 250 mg",
          "type": "DRUG"
        },
        {
          "name": "CORT125134 dose to be determined",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corcept Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2017-05-18",
      "completion_date": "2017-11-15",
      "has_results": false,
      "last_update_posted_date": "2023-10-23",
      "last_synced_at": "2026-10-26T14:55:15.618Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06094790"
    },
    {
      "nct_id": "NCT01348490",
      "title": "Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "MPN (Myeloproliferative Neoplasms)"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2011-06-15",
      "completion_date": "2018-12-19",
      "has_results": true,
      "last_update_posted_date": "2020-01-28",
      "last_synced_at": "2026-10-26T14:55:15.618Z",
      "location_count": 38,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Burbank, California + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01348490"
    }
  ]
}